<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>Impact of the COVID-19 pandemic on </b><b>healthcare resource utilization across </b><b>selected disease areas in the USA</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>Supplementary Table 1: </b>Pharmaceutical disease cohorts' characteristics</li><li><b>Supplementary Table 2: </b>Oncology disease cohorts' characteristics</li><li><b>Supplementary Table 3: </b>Disease areas and ICD-10 clinical modification diagnosis codes</li><li><b>Supplementary Table 4: </b>Total pre-pandemic and pandemic outpatient visits and the percentage change in outpatient visits for each disease area</li><li><b>Supplementary Table 5: </b>Total pre-pandemic and pandemic inpatient visits and the percentage change in inpatient visits for each disease area</li><li><b>Supplementary Table 6: </b>Total pre-pandemic and pandemic ED visits and the percentage change in ED visits for each disease area</li></ul><p dir="ltr"><b>Aim:</b> To analyze the impact of the COVID-19 pandemic on US healthcare resource utilization.<b> Methods: </b>Optum claims data were used to compare all-cause healthcare visits and healthcare spending for selected diseases between the prepandemic and pandemic periods. Telemedicine use was only assessed for the pandemic period owing to data availability. <b>Results:</b> During the first wave of the pandemic, all-cause healthcare visits across all selected disease areas displayed a rapid decline compared with the prepandemic period, followed by a period of recovery. A reduction in outpatient and home healthcare spending was observed, whereas inpatient and prescription spending increased. <b>Conclusion:</b> Changes in healthcare resource utilization trends were observed during the pandemic. The magnitude of these changes can inform subsequent studies that utilize COVID-19-era data.</p>
Funding
Development of this manuscript was funded by Novartis Pharma AG.